|Videos|March 22, 2021

Reduced SARS-CoV-2 Reinfection Risk Among the Denmark Population

An interview on perspectives learned from a nationwide PCR test database assessment.

New research from the Statens Serum Institut in Denmark last week reported nationwide PCR test result-based findings showing that COVID-19 reinfection was prevalent in just 0.65% of the country’s population through 2020.

The findings, published in The Lancet, would suggest that previously infected COVID-19 patients are likely to have a protection from reinfection at least through 6 months after testing positive.

That said, more research is being considered, and investigators additionally found stipulations among age groups.

In an interview with Contagion on her team’s findings, study author Daniela Michlmayr, PhD, explained the inspiration for the assessment that was made possible by an impressive 4 million data-logged PCR test results from Denmark—approximately two-thirds of the country’s population.

Michlmayr also discussed currently ongoing genome sequencing assessments with the same available national database, to help better inform their new interpretation of improved protection from COVID-19 reinfection.

Most importantly, Michlmayr discussed the unique age-stratified findings from the newly-published research, which shows that elderly patients fared worse than the younger population’s approximate 80% overall protection from COVID-19 reinfection.

“We found really alarming results that among the elderly, everybody who is 65 and beyond, actually had a reduced protection—only 50%, approximately,” she said. “That alarmed us, personally, and motivated us to conduct these studies.”


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.